330
Participants
Start Date
September 21, 2020
Primary Completion Date
August 30, 2021
Study Completion Date
August 30, 2021
novel oral polio type 2 vaccine (nOPV2)
• nOPV2 (C1) is a live-attenuated serotype-2 poliovirus that was derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells (S2/cre5/S15domV/rec1/hifi3). Placebo contain sucrose in buffer.
Placebo
Placebo contains no active ingradients, only sucrose in buffer
: International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka
Collaborators (1)
Bill and Melinda Gates Foundation
OTHER
Centers for Disease Control and Prevention
FED
PATH
OTHER
World Health Organization
OTHER
PT Bio Farma
INDUSTRY
International Centre for Diarrhoeal Disease Research, Bangladesh
OTHER